NCT03258554
Clinical Trial Information
Trial Number: NCT03258554 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
"Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin"
Study ID:
NRG-HN004
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT03258554-D4 | This data submission (NCT03258554-D4) contains the baseline, treatment, and adverse event data used to generate the results for the lead-in phase analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. |
| NCT03258554-D3 | This data submission (NCT03258554-D3) contains the outcome data used to generate the results for the phase II prespecified analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D4 contains data for the lead-in phase. |
| NCT03258554-D2 | This data submission (NCT03258554-D2) contains the adverse event data used to generate the results for the phase II extended follow-up analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. NCT03258554-D4 contains data for the lead-in phase. |
| NCT03258554-D1 | This data submission (NCT03258554-D1) contains baseline, treatment, and outcome data used to generate the results for the phase II extended follow-up analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. NCT03258554-D4 contains data for the lead-in phase. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®